Non-Invasive Prenatal Testing (NIPT)

NIPT (Non Invasive Prenatal Testing) is a blood screening test that is offered during pregnancy and can be administered as early as 10 weeks of gestation. This screening test is used to detect congenital abnormalities in the fetus’s DNA. The blood sample collected from the mother contains the fetus’s DNA in the form of cell free DNA (cfDNA). The test normally screens for chromosomal disorders such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) and can also be used to also determine the fetus’s sex.

Atila’s iSAFE™ Non-Invasive Prenatal Test (NIPT) Kit screens for aneuploidy (the presence of extra or missing copy of a chromosomes) for chromosomes  21, 18, and 13 in singleton pregnancies. The kit combines Atila’s multiplex PCR technology and  Digital PCR system to accurately quantify the copy numbers of chromosome 21, 18, and 13 in maternal blood cell-free DNA (cfDNA) as well as detect fetal fraction and gender determination. The kit is compatible with standard digital PCR systems.